Rapid development and testing of Zika virus vaccine candidates
寨卡病毒候选疫苗的快速开发和测试
基本信息
- 批准号:9330079
- 负责人:
- 金额:$ 19.23万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-08-15 至 2019-07-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAedesAmericasAnimal ModelAnimalsAntibioticsAntibody FormationAntibody titer measurementAntigensBiological AssayBrazilCell Culture TechniquesCellsChikungunya virusClinical TrialsCountryCulicidaeDataDengueDengue VirusDevelopmentDiseaseDisease OutbreaksElectron MicroscopyFlavivirusFrench PolynesiaGenesGenomeGoalsGoldGrowthHemagglutinationHeterophile AntigensHumanImmunityImmunocompetentImmunocompromised HostIn VitroInterferon ReceptorInternationalKnockout MiceLinkMembraneMembrane ProteinsMethodsMexicoMicrocephalyMicronesiaModelingModified Vaccinia Virus AnkaraMothersMusPhilippinesPoxviridaeProcessReportingResistanceSCID MiceSafetySerumSmallpoxSmallpox VirusesStructureTestingTetracyclinesVaccinatedVaccinesVaccinia virusVirus DiseasesVirus-like particleWestern BlottingZika VirusZika virus vaccinebasecell mediated immune responsedesignefficacy testingenv Gene Productsimmunogenicitymouse modelneutralizing antibodynovelpreclinical studyprotein expressionpublic health emergencyvaccine candidatevaccine developmentvaccine efficacyvaccinia virus vectorvectorviral vector developmentvirus envelope
项目摘要
PROJECT SUMMARY
Zika virus (ZIKV) is an enveloped flavivirus transmitted by Aedes mosquitos which leads to an
asymptomatic or mild dengue-like disease. A large ZIKV outbreak started in Brazil in early 2015, recently
spreading to more than 25 countries in the Americas. Alarmingly, the ZIKV Brazilian outbreak has been
linked to thousands of microcephaly cases in babies born to infected mothers, leading the WHO to
recently declare a Public Health Emergency of International Concern. Thus, control efforts are
desperately needed to contain the outbreaks and avoid further spread to other countries. No ZIKV
vaccines have been developed, although vaccines for the related dengue virus (DENV) based on the
Membrane (M) and Envelope (E) proteins, which induce protective immunity, are in advanced clinical
trials, and one (Dengvaxia) was just approved in Mexico, Brazil, and the Philippines. Vaccinia virus
(VACV) was used to eradicate smallpox, a disease caused by variola virus, a related poxvirus. VACV has
also been successfully used as a replication-competent or -defective viral vector for the development of
effective human and animal vaccines, as it elicits strong and long-lasting humoral and cell-mediated
immune (CMI) responses to heterologous antigens expressed in its genome. We recently generated
VACV vectors with a built-in safety mechanism that replicate only in the presence of tetracycline
antibiotics. When administered as a vaccine (in the absence of antibiotics), the vector does not replicate
but retains its immunogenicity, and therefore is safer for human use. Conveniently, the vector can be
propagated in cell culture at high titers in the presence of tetracyclines, unlike other replication-defective
VACV-based vectors such as modified vaccinia Ankara (MVA). More recently, we developed a novel
method to generate and purify recombinant VACV vaccines without the use of selection markers in as
little as one week, a process that normally takes months. Our goal is to use this method to rapidly
generate recombinant VACV vaccines expressing the ZIKV E and M proteins and to test their
immunogenicity, safety, and efficacy in mice. In Aim 1 we will rapidly generate and characterize
replication-defective VACV vaccine candidates expressing the ZIKV E protein (VACV-ZIKVs). A number
of ZIKV E and M-E gene constructs were designed for expression of E alone or as virus-like particles
(VLPs) to maximize induction of serum neutralizing (SN) antibodies. In Aim 2 we will test the
immunogenicity (SN titers and CMI responses) and safety of VACV-ZIKV vaccine candidates in mice.
Concurrently, in Aim 3 we will develop a ZIKV mouse challenge model based on current models for the
related DENV to test the efficacy of our VACV-ZIKV vaccine candidates. Our goal is to use our
accelerated VACV platform to rapidly select the best antigen strategy that leads to high levels of SN
antibody production, CMI responses, and protection in mice.
项目总结
寨卡病毒(ZIKV)是一种由伊蚊传播的包膜黄病毒,可导致
无症状或轻微的登革热样疾病。巴西于2015年初爆发了一场大规模的寨卡病毒疫情,最近
传播到美洲超过25个国家。令人震惊的是,巴西ZIKV疫情一直在
与感染病毒母亲所生婴儿的数千例小头畸形症有关,导致世卫组织
最近宣布进入国际关注的突发公共卫生事件。因此,控制努力是
迫切需要控制疫情,避免进一步蔓延到其他国家。没有ZIKV
尽管相关登革热病毒(DENV)的疫苗是基于
膜蛋白(M)和包膜蛋白(E)可诱导保护性免疫,已进入晚期临床
一种(登革热)药物刚刚在墨西哥、巴西和菲律宾获得批准。牛痘病毒
(VACV)被用来根除天花,天花是一种由天花病毒引起的疾病,天花病毒是一种相关的痘病毒。VACV有
也被成功地用作复制能力或缺陷病毒载体用于开发
有效的人和动物疫苗,因为它能产生强大而持久的体液和细胞介导性疫苗
对其基因组中表达的异源抗原的免疫(CMI)反应。我们最近生成了
VACV载体具有内置的安全机制,仅在四环素存在时复制
抗生素。当作为疫苗接种时(在没有抗生素的情况下),载体不会复制。
但保留了其免疫原性,因此对人类使用更安全。方便的是,向量可以
在四环素存在的情况下在细胞培养中以高滴度繁殖,与其他复制缺陷不同
以VACV为基础的载体,如改良的安卡拉牛痘(MVA)。最近,我们开发了一部小说
一种在AS中不使用选择标记的重组VACV疫苗的制备和纯化方法
短短一周,这个过程通常需要几个月的时间。我们的目标是使用这种方法快速
构建表达ZIKV E和M蛋白的重组VACV疫苗
对小鼠的免疫原性、安全性和有效性。在目标1中,我们将快速生成和描述
表达ZIKV E蛋白的复制缺陷VACV候选疫苗(VACV-ZIKV)。一个数字
ZIKV E和M-E基因构建体被设计为单独表达E或作为病毒样颗粒表达
(VLP)以最大限度地诱导血清中和(SN)抗体。在目标2中,我们将测试
VACV-ZIKV候选疫苗在小鼠中的免疫原性(SN滴度和CMI反应)和安全性。
同时,在目标3中,我们将在现有模型的基础上开发ZIKV小鼠挑战模型
相关DENV来测试我们的VACV-ZIKV候选疫苗的效力。我们的目标是用我们的
加速VACV平台,快速选择导致高水平SN的最佳抗原策略
小鼠的抗体产生、CMI反应和保护。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Single dose of a replication-defective vaccinia virus expressing Zika virus-like particles is protective in mice.
- DOI:10.1038/s41598-021-85951-7
- 发表时间:2021-03-22
- 期刊:
- 影响因子:4.6
- 作者:Jasperse B;O'Connell CM;Wang Y;Verardi PH
- 通讯作者:Verardi PH
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PAULO H VERARDI其他文献
PAULO H VERARDI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PAULO H VERARDI', 18)}}的其他基金
Vaccines for Prevention of RG3 and RG4 Emerging Tickborne Viral Deseases
用于预防 RG3 和 RG4 新出现蜱传病毒性疾病的疫苗
- 批准号:
9990349 - 财政年份:2021
- 资助金额:
$ 19.23万 - 项目类别:
Vaccines for Prevention of RG3 and RG4 Emerging Tickborne Viral Diseases
用于预防 RG3 和 RG4 新出现蜱传病毒性疾病的疫苗
- 批准号:
10472452 - 财政年份:2021
- 资助金额:
$ 19.23万 - 项目类别:
Vaccines for Prevention of RG3 and RG4 Emerging Tickborne Viral Diseases
用于预防 RG3 和 RG4 新出现蜱传病毒性疾病的疫苗
- 批准号:
10673195 - 财政年份:2021
- 资助金额:
$ 19.23万 - 项目类别:
Rapid development of replication-controlled vaccinia virus vectors for vaccines and therapeutics with single or double safety features
快速开发复制控制的痘苗病毒载体,用于具有单一或双重安全特征的疫苗和疗法
- 批准号:
9230098 - 财政年份:2016
- 资助金额:
$ 19.23万 - 项目类别:
SMART Virus Vectors with a Built-in Safety Mechanism
具有内置安全机制的 SMART 病毒载体
- 批准号:
6761381 - 财政年份:2004
- 资助金额:
$ 19.23万 - 项目类别:
SMART Virus Vectors with a Built-in Safety Mechanism
具有内置安全机制的 SMART 病毒载体
- 批准号:
6874942 - 财政年份:2004
- 资助金额:
$ 19.23万 - 项目类别:
相似海外基金
Defining the antiviral effects of Wolbachia in Aedes aegypti mosquitoes
确定沃尔巴克氏体对埃及伊蚊的抗病毒作用
- 批准号:
DP220102997 - 财政年份:2023
- 资助金额:
$ 19.23万 - 项目类别:
Discovery Projects
The molecular basis of fatty acid taste in Aedes aegypti
埃及伊蚊脂肪酸味道的分子基础
- 批准号:
10679953 - 财政年份:2023
- 资助金额:
$ 19.23万 - 项目类别:
Molecular and functional characterization of olfactory pathways in the arbovirus vector mosquito Aedes aegypti
虫媒病毒载体蚊子埃及伊蚊嗅觉通路的分子和功能特征
- 批准号:
10638710 - 财政年份:2023
- 资助金额:
$ 19.23万 - 项目类别:
Collaborative Research: Olfactory learning and neuromodulation in the Aedes aegypti mosquito
合作研究:埃及伊蚊的嗅觉学习和神经调节
- 批准号:
2242603 - 财政年份:2023
- 资助金额:
$ 19.23万 - 项目类别:
Standard Grant
Collaborative Research: Olfactory learning and neuromodulation in the Aedes aegypti mosquito
合作研究:埃及伊蚊的嗅觉学习和神经调节
- 批准号:
2242604 - 财政年份:2023
- 资助金额:
$ 19.23万 - 项目类别:
Standard Grant
Genomic Analysis of Aedes aegypti Host Preference Across Urban-Rural Gradients in Africa
非洲城乡梯度埃及伊蚊寄主偏好的基因组分析
- 批准号:
10525807 - 财政年份:2023
- 资助金额:
$ 19.23万 - 项目类别:
Exploring the coevolutionary potential of chikungunya virus and its Aedes mosquito vectors
探索基孔肯雅病毒及其伊蚊媒介的共同进化潜力
- 批准号:
10711906 - 财政年份:2023
- 资助金额:
$ 19.23万 - 项目类别:
The development of biorational pesticides targeting lncRNAs in adult female Aedes aegypti mosquitoes
针对成年雌性埃及伊蚊 lncRNA 的生物合理农药的开发
- 批准号:
10742558 - 财政年份:2023
- 资助金额:
$ 19.23万 - 项目类别:
Doctoral Dissertation Research: Phylogeographic Investigation of Aedes aegypti
博士论文研究:埃及伊蚊的系统发育地理学调查
- 批准号:
2210879 - 财政年份:2022
- 资助金额:
$ 19.23万 - 项目类别:
Standard Grant
Developing novel genetic and symbiotic control strategies for the invasive mosquito, Aedes japonicus
为入侵性蚊子日本伊蚊开发新型遗传和共生控制策略
- 批准号:
BB/W018446/1 - 财政年份:2022
- 资助金额:
$ 19.23万 - 项目类别:
Research Grant